Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,938,000 | 3,045,200 | 1,132,300 | 769,000 | 862,800 |
| Marketable Securities | 1,288,300 | 930,700 | 500,500 | 446,300 | 604,000 |
| Receivables | 912,100 | 727,400 | 828,100 | 699,100 | 664,900 |
| Inventories | 1,126,200 | 1,086,700 | 903,500 | 875,500 | 726,700 |
| Other current assets | 339,300 | 374,400 | 542,500 | 195,900 | 237,100 |
| TOTAL | $6,738,900 | $6,285,400 | $4,035,700 | $3,095,800 | $3,180,700 |
| Non-Current Assets | |||||
| PPE Net | 1,811,900 | 1,686,000 | 1,591,000 | 1,632,800 | 1,546,600 |
| Investments And Advances | 278,600 | 307,900 | 583,900 | 1,239,000 | 1,834,200 |
| Intangibles | 2,896,800 | 2,953,300 | 1,544,500 | 1,449,500 | 1,491,500 |
| Other Non-Current Assets | 1,971,000 | 1,822,700 | 1,608,100 | 875,400 | 449,600 |
| TOTAL | $6,958,300 | $6,769,900 | $5,327,500 | $5,196,700 | $5,321,900 |
| Total Assets | $13,697,200 | $13,055,300 | $9,363,200 | $8,292,500 | $8,502,600 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 227,500 | 197,400 | 186,600 | 201,900 | 204,500 |
| Accrued Expenses | 1,561,700 | 1,282,400 | 856,400 | 795,000 | 802,300 |
| TOTAL | $1,813,700 | $1,505,200 | $1,195,400 | $1,022,400 | $1,032,300 |
| Non-Current Liabilities | |||||
| Long Term Debt | 598,300 | 597,700 | 597,000 | 596,300 | 595,700 |
| Other Non-Current Liabilities | 951,700 | 894,400 | 854,400 | 867,100 | 1,038,700 |
| TOTAL | $1,545,900 | $1,487,200 | $1,448,400 | $1,463,400 | $1,634,400 |
| Total Liabilities | $3,359,600 | $2,992,400 | $2,643,800 | $2,485,800 | $2,666,700 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 580,800 | 587,900 | 601,300 | 608,313 | 623,207 |
| Common Shares | 658,700 | 654,800 | 650,500 | 646,300 | 642,000 |
| Retained earnings | 14,240,500 | 13,167,000 | 8,992,400 | 7,590,000 | 6,068,100 |
| Other shareholders' equity | -238,000 | -180,300 | -172,900 | -254,900 | -157,600 |
| TOTAL | $10,337,600 | $10,062,900 | $6,719,400 | $5,806,700 | $5,835,900 |
| Total Liabilities And Equity | $13,697,200 | $13,055,300 | $9,363,200 | $8,292,500 | $8,502,600 |